scholarly journals Severe paraneoplastic hypoglycemia due to a non-islet cell tumor in a patient with an advanced gastrointestinal stromal tumor

2020 ◽  
Author(s):  
Maurizio Alletto ◽  
Antonio Burgio ◽  
Giovanni Fulco ◽  
Giulio Geraci ◽  
Concetta Groppuso ◽  
...  
Keyword(s):  
Growth Factor ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Growth Factor Receptor ◽  
Cell Tumor ◽  
Tyrosine Kinase Receptors ◽  
Β Cells ◽  
Mesenchymal Tumors ◽  
Metastatic Gist ◽  
Tumor Hypoglycemia

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, mainly localized in the stomach. Most GIST derive from mutations in tyrosine kinase receptors (KIT) or platelet-derived growth factor receptor-α (PDGFRA). GISTs are rarely associated with paraneoplastic hypoglycemia caused by non-β-cells tumor. This syndrome, defined non-islet cell tumor hypoglycemia (NICTH), arises from excess tumor production of insulin-like growth factor. We describe a 67-year-old female with severe NICTH secondary to an advanced and metastatic GIST.

scholarly journals A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia

2005 ◽  
Vol 90 (7) ◽  
pp. 3819-3823 ◽  
Author(s):  
Farideh Miraki-Moud ◽  
Ashley B. Grossman ◽  
Michael Besser ◽  
John P. Monson ◽  
Cecilia Camacho-Hübner
Keyword(s):  
Growth Factor ◽  
Rapid Method ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Tumor Hypoglycemia

scholarly journals Characterization of Insulin-Like Growth Factor II(IGF-II) and IGF Binding Proteins in Patients with Non-Islet-Cell Tumor Hypoglycemia.

1993 ◽  
Vol 40 (1) ◽  
pp. 111-119 ◽  
Author(s):  
IZUMI FUKUDA ◽  
NAOMI HIZUKA ◽  
KAZUE TAKANO ◽  
KUMIKO ASAKAWA-YASUMOTO ◽  
KAZUO SHIZUME ◽  
...  
Keyword(s):  
Growth Factor ◽  
Islet Cell ◽  
Binding Proteins ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Igf Binding Proteins ◽  
Factor Ii ◽  
Igf Binding ◽  
Tumor Hypoglycemia

A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II

2010 ◽  
Vol 60 (8) ◽  
pp. 595-597 ◽  
Author(s):  
Hiroshi Maruyama ◽  
Mitsutoshi Tatsumi ◽  
Hitoshi Kitayama ◽  
Yasunori Enomoto ◽  
Hiroki Kuniyasu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Tumor Hypoglycemia

scholarly journals Serum Insulin-Like Growth Factor II in 44 Patients with Non-Islet Cell Tumor Hypoglycemia

1998 ◽  
Vol 45 (Suppl) ◽  
pp. S61-S65 ◽  
Author(s):  
NAOMI HIZUKA ◽  
IZUMI FUKUDA ◽  
KAZUE TAKANO ◽  
YUMIKO OKUBO ◽  
KUMIKO ASAKAWA-YASUMOTO ◽  
...  
Keyword(s):  
Growth Factor ◽  
Islet Cell ◽  
Serum Insulin ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Tumor Hypoglycemia

Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia

2006 ◽  
Vol 16 (4) ◽  
pp. 211-216 ◽  
Author(s):  
Izumi Fukuda ◽  
Naomi Hizuka ◽  
Yukiko Ishikawa ◽  
Kumiko Yasumoto ◽  
Yuko Murakami ◽  
...  
Keyword(s):  
Growth Factor ◽  
Clinical Features ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Tumor Hypoglycemia

scholarly journals A Case of Non-Islet Cell Tumor Hypoglycemia in Metastatic Solitary Fibrous Tumor

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A1035-A1036
Author(s):  
Lakshmi Priyanka Mahali ◽  
Beatrice Wong
Keyword(s):  
Blood Glucose ◽  
Growth Factor ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Serum Glucose ◽  
Capillary Blood ◽  
Cell Tumor ◽  
Capillary Blood Glucose ◽  
Fibrous Tumor ◽  
Tumor Hypoglycemia

Abstract Introduction: Insulin like growth factor (IGF-2) mediated hypoglycemia secondary to solitary fibrous tumor (SFT), also known as Doege-Potter syndrome is a rare paraneoplastic syndrome. The tumor cells produce large amounts of high molecular weight IGF 2 precursor protein called “big IGF-2” which binds to insulin and IGF receptors in liver, muscle and other peripheral tissues. This causes reduced gluconeogenesis and increased uptake of glucose by the muscle and other tissues leading to hypoglycemia. Big IGF-2 also exerts central negative feedback of growth hormone causing reduction of IGF-I production. Most SFTs are benign and localized (approximately 78-88%). As a result, tumor excision alone would often lead to resolution of the hypoglycemia. We present a case of metastatic SFT with multiple metastasis managed with oral prednisone. Clinical Case: A 44-year-old man with metastatic SFT presented with bilateral humeral fractures. He has known metastatic disease to the brain, lung, liver, bony lytic lesions over a course of eleven years. It has progressed despite multiple chemotherapy and radiation therapies. Prior to admission, he had multiple syncopal episodes associated with fasting hypoglycemia. He reported capillary blood glucose values ranging between 30-50 mg/dl during these episodes which would improve after drinking juice or eating candy. There was no history of diabetes mellitus or use of oral hypoglycemic agents or insulin. On admission, he had a capillary blood glucose value of less than 20 mg/dl, which was confirmed by a serum glucose value of 18 mg/dl on basic metabolic panel. His renal, liver and thyroid function tests were normal. Significant labs include: serum glucose 17 mg/dl, C-peptide <0.10 ng/ml (n: 1-4 ng/ml), serum insulin <1.6 Uu/ml (n: <20 Uu/ml), beta-hydroxybutyrate <0.2 mmol/L (n: <0.3), cortisol 10.8 ug/dl(n: 5-15 ug/dl) glucagon 6 pg/ml(ref 8-57 pg/ml), insulin-like growth factor-1 (IGF 1) 20 ng/ml (n: 52-328), and IGF-2 level 380 ng/ml (267-616 ng/ml), improvement in blood glucose from 46 to 111 mg/dl after 1-gram glucagon administration. The IGF-2/IGF-1 ratio of 19 confirmed our clinical suspicion of non-islet cell tumor hypoglycemia (NICTH). He was started on prednisone 20 mg twice daily with marked improvement in hypoglycemia. Conclusion: NICTH is a rare cause of hypoglycemia and should be considered in the differential while evaluating hypoglycemia in malignancy. For diagnosing NICTH, assays for big IGF-II are not commercially available. However, the IGF-II:IGF-I ratio is considered to be a surrogate marker of big IGFII concentration. The normal ratio is 3 and ratio >10 is diagnostic of NICTH. In cases like ours where tumor resection is not possible, glucocorticoids are most effective in management of hypoglycemia by inhibiting big IGF2 production and stimulating gluconeogenesis.

scholarly journals A case of carcinoma of the maxillary gingiva with insulin-like growth factor II producing non-islet-cell tumor hypoglycemia

2016 ◽  
Vol 62 (9) ◽  
pp. 448-453
Author(s):  
Hidetaka MIYASHITA ◽  
Seiji ASODA ◽  
Taisuke MORI ◽  
Yuka YAMADA ◽  
Tomoya SOMA ◽  
...  
Keyword(s):  
Growth Factor ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Tumor Hypoglycemia
Sign in / Sign up

Export Citation Format

Share Document